reports
Cormedix Inc: 1 director
A director at Cormedix Inc bought 6,000 shares at 3.375USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
- Jonathan Moreland
VLY VALLEY NATIONAL BANCORP
TPC TUTOR PERINI CORPORATION
TNDM TANDEM DIABETES CARE INC
TCBI TEXAS CAPITAL BANCSHARES INC.
RYAM RAYONIER ADVANCED MATERIALS INC
PNNT PENNANTPARK INVESTMENT
FARO FARO TECHNOLOGIES INC.
CRMD CORMEDIX INC.
CNO CNO FINANCIAL GROUP INC.
CMRX CHIMERIX INC
ATSG AIR TRANSPORT SERVICES GROUP INC.
GLDD GREAT LAKES DREDGE & DOCK CORPORATION
NNBR NN
AVDL INC.
QNST AVADEL PHARMACEUTICALS ADS
MPB QUINSTREET
INVA MID PENN BANCORP INC.
ACCD INOVA TECH
NRGX ACCOLADE
EMO INC.
GER PIMCO ENERGY & TACTICAL CREDIT OPPORTUNITIES FUND
PRAA CLEARBRIDGE ENERGY MLP OPPORTUNITY FUND INC.
GOLDMAN SACHS MLP & ENER RENAISS FD
PORTFOLIO RECOVERY ASSOCIATES
INC.
- Jonathan Moreland
OXY OCCIDENTAL PETROLEUM CORPORATION
WHF WHITEHORSE FINANCE INC.
PNNT PENNANTPARK INVESTMENT
NVTA INVITAE CORP
EGBN EAGLE BANCORP INC.
CRMD CORMEDIX INC.
AVD AMERICAN VANGUARD
RBA RITCHIE BROS. AUCTIONEERS INCORPORATED
ADC AGREE REALTY CORPORATION
BOKF BOK FINANCIAL CORPORATION
HTLD HEARTLAND EXPRESS INC.
ALOT ASTRONOVA INC.
SNAP SNAP INC. CLASS A
RGCO RGC RESOURCES
WTBA WEST BANCORP INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
LRMR LARIMAR THERAPEUTICS INC
DCOM DIME COMMUNITY BANCSHARES
LAZR INC.
FSBC LUMINAR TECHNOLOGIES INC (A)
UGRO FIVE STAR BANCORP
URBAN GRO INC
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange
CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has been approved for listing on the Nasdaq Global Market. The company’s shares will continue to trade under its current symbol “CRMD”. Trading on the Nasdaq Global Market is expected to commence on Tuesday, February 2, 2021. The Company’s shares of co...
CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting f...
CorMedix Inc. Announces FDA Decision That Advisory Committee Meeting for New Drug Application for Defencath is Not Needed PDUFA date remains February 28, 2021Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the...
CorMedix Inc. Reports Third Quarter 2020 Financial Results and Provide...
CorMedix Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the third quarter and nine months ended September 30, 2020 and provided an update on recent developments. Recent Corporate and Regulatory ...
CorMedix Appoints Greg Duncan to its Board of Directors
CorMedix Appoints Greg Duncan to its Board of Directors Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector BERKELEY HEIGHTS, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Greg Duncan to its Board of Directors. Greg will replace Dr. Mehmood Khan, who is stepping down from the Board due to policie...
CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provi...
CorMedix Inc. to Report Third Quarter 2020 Financial Results and Provide a Corporate Update on November 5 BERKELEY HEIGHTS, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the third quarter ended September 30, 2020, after the market close on Thursday, November 5, and will host a corporate update conference call at 4:30pm EST. Thursday, No...
- Jonathan Moreland
LJPC LA JOLLA PHARMACEUTICAL COMPANY
LBTYA LIBERTY GLOBAL PLC CLASS A
CRMD CORMEDIX INC.
BDGE BRIDGE BANCORP INC.
CERC CERECOR INC
RILY B RILEY SECURITIES INC
CZFS CITIZENS FINANCIAL SERVICES INC.
GBDC GOLUB CAPITAL BDC INC.
WLL WHITING PETROLEUM CORPORATION
ODT ODONATE THERAPEUTICS INC
TENX TENAX THERAPEUTICS
RCUS ARCUS BIOSCIENCES
LIVX LIVEXLIVE MEDIA
VAPO VAPOTHERM INC
XRX XEROX HOLDINGS CORPORATION
IGMS IGM BIOSCIENCES
TCON TRACON PHARMACEUTICALS
CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Inv...
CorMedix Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference BERKELEY HEIGHTS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the virtual H.C. Wainwright 22nd Annual Global Investment Conference taking place on September 14 – 16, 2020. H.C. Wainwright 22nd Annual Global Investment Conference...
- Jonathan Moreland
CRMD CORMEDIX INC.
CCNE CNB FINANCIAL CORP. (PENNSYLVANIA)
CAR AVIS BUDGET GROUP INC.
CBFV CB FINANCIAL SERVICES INC.
PCYO PURE CYCLE CORP.
LIND LINDBLAD EXPEDITIONS HOLDINGS
CNBKA CENTURY BANCORP INC. CL A
XPER XPERI HOLDING CORPORATION
KRMD REPRO MED SYSTEMS
CSBB C S B BANCORP OHIO
THM INTERNATIONAL TOWER HILL MINES LTD
LIVX LIVEXLIVE MEDIA
PRTS U.S. AUTO PARTS NETWORK
IMVT INC.
RZLT IMMUNOVANT INC
REZOLUTE
INC.
- Jonathan Moreland
XOMA XOMA
SREV SERVICESOURCE INTERNATIONAL INC.
PRTY PARTY CITY HOLDCO INC.
CRMD CORMEDIX INC.
AXS AXIS CAPITAL HOLDINGS LIMITED
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
CNBKA CENTURY BANCORP INC. CL A
RESI FRONT YARD RESIDENTIAL CORP. CLASS B
TACO TACO CABANA INC.
ELAN ELANCO ANIMAL HEALTH INC.
KOD KODIAK SCIENCES
VAPO VAPOTHERM INC
XRX XEROX HOLDINGS CORPORATION
EVF EATON VANCE SENIOR INCOME TRUST
FLUX FLUX POWER HOLDINGS INC
CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review ...
CorMedix Inc. Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Defencath FDA sets PDUFA goal date of February 28, 2021Potentially the first antibacterial and antifungal catheter lock solution in the US to prevent catheter related infections in hemodialysis patients BERKELEY HEIGHTS, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that the U.S. F...
- Jonathan Moreland
XOMA XOMA
SMRTQ STEIN MART INC.
GTIM GOOD TIMES RESTAURANTS INC
CYTR CYTRX CORPORATION
CRMD CORMEDIX INC.
AGRX AGILE THERAPEUTICS
HTBI HOMETRUST BANCSHARES INC
TACO TACO CABANA INC.
PRVB PROVENTION BIO INC
RRR RSC HOLDINGS
VEL INC.
EVF VELOCITY COMPOSITES
EATON VANCE SENIOR INCOME TRUST
- Jonathan Moreland
RM REGIONAL MANAGEMENT CORP
FPR ALTO INGREDIENTS INC
FSB FRANKLIN FINANCIAL NETWORK INC
CSII CARDIOVASCULAR SYSTEMS INC.
CRMD CORMEDIX INC.
KRNY KEARNY FINANCIAL CORP.
NAVI NAVIENT CORP
GBDC GOLUB CAPITAL BDC INC.
FLNT FLUENT INC
VRCA VERRICA PHARMACEUTICALS
PRVB PROVENTION BIO INC
NGM NGM BIOPHARMACEUTICALS
VAPO VAPOTHERM INC
UTGN UTG
RRR RSC HOLDINGS
AVDL INC.
ACI AVONDALE INDUSTRIES INC.
CVLB ALBERTSONS COMPANIES
INC.
CONVERSION LABS
INC.
CorMedix Inc. Reports Second Quarter and Six Month 2020 Financial Resu...
CorMedix Inc. Reports Second Quarter and Six Month 2020 Financial Results and Provides Business Update Conference Call Scheduled for Today at 4:30 p.m. Eastern Time BERKELEY HEIGHTS, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the second quarter and six months ended June 30, 2020 and provided an update on recent developments. Recent Corporate and Regulato...
CorMedix Inc. to Report Second Quarter 2020 Financial Results and Prov...
CorMedix Inc. to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 10 BERKELEY HEIGHTS, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Monday, August 10, and will host a corporate update conference call at 4:30pm Eastern Time. Monday, Au...
CorMedix Announces Pricing of $20M Public Offering of Common Stock
CorMedix Announces Pricing of $20M Public Offering of Common Stock BERKELEY HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it has priced its underwritten public offering of 4,444,444 shares of its common stock at $4.50 per share for total gross proceeds, before underwriting commissions and estimated expenses, of approximately $20 million. In connection ...
CorMedix Announces Proposed Public Offering of Common Stock
CorMedix Announces Proposed Public Offering of Common Stock BERKELEY HEIGHTS, N.J., July 27, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, announced today that it plans to offer shares of its common stock in an underwritten public offering. In connection with the offering, the Company intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common st...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.